Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 238 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post Menopausal Clear all
Completed No phase listed Observational

Sex, Aging and Antiretroviral Pharmacokinetics

NCT00666055
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen chosen by treating physician
Drug
Lead sponsor
Kristine Patterson, MD
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Jul 21, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Results available

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

NCT02770768
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

NCT02865538
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
BAY3427080, Placebo (for BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
DeLand, Florida • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jul 21, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

NCT00880009
View directory record Official record
Conditions
Breast Cancer
Interventions
Bosutinib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Jul 21, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

NCT06139107
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Mridula George, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

NCT00471237
View directory record Official record
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, fulvestrant
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
418
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 289 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 21, 2026, 4:48 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

NCT02483195
View directory record Official record
Conditions
Female Androgenetic Alopecia
Interventions
5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

NCT01901679
View directory record Official record
Conditions
Obesity
Interventions
Celebrex
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 21, 2026, 4:48 PM EDT
Active, not recruiting Phase 4 Interventional

Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream

NCT05723601
View directory record Official record
Conditions
Recurrent Urinary Tract Infection
Interventions
Estradiol vaginal cream, Estradiol Vaginal Tablet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

NCT01248494
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
BEZ235, BKM 120, Letrozole, BKM120
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 21, 2026, 4:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Calcium Absorption in Postmenopausal Thai Women

NCT02291315
View directory record Official record
Conditions
Fractional Calcium Absorption
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
53 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

NCT01808040
View directory record Official record
Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
TAK700
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 21, 2026, 4:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00291083
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Jul 21, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

NCT00499681
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, letrozole, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 4 Interventional

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
View directory record Official record
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jul 21, 2026, 4:48 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

NCT00565916
View directory record Official record
Conditions
Postmenopausal Syndrome
Interventions
Estrogen, Progesterone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adherence and Health Effects of Video Dance in Postmenopausal Women

NCT01443455
View directory record Official record
Conditions
Post Menopausal
Interventions
videodance, Brisk Walking, delayed entry control
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

NCT03432533
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

NCT01186796
View directory record Official record
Conditions
Healthy
Interventions
Fulvestrant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Jul 21, 2026, 4:48 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT02859285
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo vulvar cream, Estradiol vulvar cream
Other
Lead sponsor
ProHealth Care, Inc
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Jul 21, 2026, 4:48 PM EDT